A compound, wherein: (a) the compound is represented by Formula: or a pharmaceutically acceptable salt thereof, wherein: D is L 1 is -CH 2 O- ∗ or -CH 2 CH 2 O- ∗, and "- ∗ " indicates the attachment point to A; L 2 is selected from the group consisting of -CH 2 - ∗, -CH 2 CH 2 - ∗, -CH 2 CH 2 CH 2 - ∗, - CH(CH 3)- ∗, -CH(CH 3)CH 2 - ∗, -CH 2 O- ∗, and -CH 2 CH 2 O- ∗, and "- ∗ " indicates the attachment point to W; R 1 and R 2 are each hydrogen or C 1 -C 6 alkyl; A is phenyl optionally substituted with 1-2 R Y; W is phenyl or 5-6 membered heteroaryl, wherein the phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R Y; each R X is oxo or -OR A; each R Y is independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, halo-C 1 -C 6 alkoxy, halo, cyano, -OR A, -NR B R C, - S 2 R D, -S(R F) m, or G 1; or 2 R Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered cycloalkyl, 3-7 membered heterocyclyl, aryl, or 5-6 membered heteroaryl, optionally substituted with 1-5 R X; each G 1 is independently phenyl optionally substituted with 1-3 R Z; each R Z is independently C 1 -C 6 alkyl; R A is, at each occurrence, independently hydrogen, C 1 -C 6 alkyl, or halo-C 1 -C 6 alkyl; each of R B and R C is independently hydrogen or C 1 -C 6 alkyl; each R D is independently C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, or -NR B1 R C1; each R F is independently hydrogen, C 1 -C 6 alkyl, halo, or halo-C 1 -C 6 alkyl; each of R B1 and R C1 is independently hydrogen or C 1 -C 6 alkyl; and m is 1, 3, or 5, or (b) the compound is selected from the group consisting of: and a pharmaceutically acceptable salt thereof. (a) the compound is represented by Formula: or a pharmaceutically acceptable salt thereof, wherein: D is L 1 is -CH 2 O- ∗ or -CH 2 CH 2 O- ∗, and "- ∗ " indicates the attachment point to A; L 2 is selected from the group consisting of -CH 2 - ∗, -CH 2 CH 2 - ∗, -CH 2 CH 2 CH 2 - ∗, - CH(CH 3)- ∗, -CH(CH 3)CH 2 - ∗, -CH 2 O- ∗, and -CH 2 CH 2 O- ∗, and "- ∗ " indicates the attachment point to W; R 1 and R 2 are each hydrogen or C 1 -C 6 alkyl; A is phenyl optionally substituted with 1-2 R Y; W is phenyl or 5-6 membered heteroaryl, wherein the phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R Y; each R X is oxo or -OR A; each R Y is independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, halo-C 1 -C 6 alkoxy, halo, cyano, -OR A, -NR B R C, - S 2 R D, -S(R F) m, or G 1; or 2 R Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered cycloalkyl, 3-7 membered heterocyclyl, aryl, or 5-6 membered heteroaryl, optionally substituted with 1-5 R X; each G 1 is independently phenyl optionally substituted with 1-3 R Z; each R Z is independently C 1 -C 6 alkyl; R A is, at each occurrence, independently hydrogen, C 1 -C 6 alkyl, or halo-C 1 -C 6 alkyl; each of R B and R C is independently hydrogen or C 1 -C 6 alkyl; each R D is independently C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, or -NR B1 R C1; each R F is independently hydrogen, C 1 -C 6 alkyl, halo, or halo-C 1 -C 6 alkyl; each of R B1 and R C1 is independently hydrogen or C 1 -C 6 alkyl; and m is 1, 3, or 5, or L 1 is -CH 2 O- ∗ or -CH 2 CH 2 O- ∗, and "- ∗ " indicates the attachment point to A; L 2 is selected from the group consisting of -CH 2 - ∗, -CH 2 CH 2 - ∗, -CH 2 CH 2 CH 2 - ∗, - CH(CH 3)- ∗, -CH(CH 3)CH 2 - ∗, -CH 2 O- ∗, and -CH 2 CH 2 O- ∗, and "- ∗ " indicates the attachment point to W; R 1 and R 2 are each hydrogen or C 1 -C 6 alkyl; A is phenyl optionally substituted with 1-2 R Y; W is phenyl or 5-6 membered heteroaryl, wherein the phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 R Y; each R X is oxo or -OR A; each R Y is independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, halo-C 1 -C 6 alkoxy, halo, cyano, -OR A, -NR B R C, - S 2 R D, -S(R F) m, or G 1; or 2 R Y groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered cycloalkyl, 3-7 membered heterocyclyl, aryl, or 5-6 membered heteroaryl, optionally substituted with 1-5 R X; each G 1 is independently phenyl optionally substituted with 1-3 R Z; each R Z is independently C 1 -C 6 alkyl; R A is, at each occurrence, independently hydrogen, C 1 -C 6 alkyl, or halo-C 1 -C 6 alkyl; each of R B and R C is independently hydrogen or C 1 -C 6 alkyl; each R D is independently C 1 -C 6 alkyl, halo-C 1 -C 6 alkyl, or -NR B1 R C1; each R F is independently hydrogen, C 1 -C 6 alkyl, halo, or halo-C 1 -C 6 alkyl; each of R B1 and R C1 is independently hydrogen or C 1 -C 6 alkyl; and m is 1, 3, or 5, or (b) the compound is selected from the group consisting of: and a pharmaceutically acceptable salt thereof.